In December 2022, the Patented Medicine Prices Review Board (PMPRB) advised that the new guidelines would not be implemented on 1 January 2023, and that the interim guidance it issued on 18 August 2022 will remain in place until further notice.

The comment period on the proposed guidelines closed on 5 December 2022 (for further details, see "Draft revised PMPRB guidelines released for comment by 5 December 2022"). 88 submissions were provided (see the "Submissions" tab), including from Health Canada.

Health Canada asked PMPRB to consider pausing the consultation process, reasoning that "[a] pause will allow time to work collaboratively, with all stakeholders and health system partners, to understand fully the short and long-term impacts of the proposed new Guidelines".

For further information on this topic please contact Daphne Lainson or Urszula Wojtyra at Smart & Biggar by telephone (+1 416 593 5514) or email ([email protected] or [email protected]). The Smart & Biggar website can be accessed at